within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX07_Fampridine;

model Fampridine
  extends Pharmacolibrary.Drugs.ATC.N.N07XX07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N07XX07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fampridine (also known as 4-aminopyridine, dalfampridine) is a potassium channel blocker used to improve walking in adults with multiple sclerosis (MS). It is approved and marketed for symptomatic treatment in MS patients to enhance walking speed.</p><h4>Pharmacokinetics</h4><p>Single-dose pharmacokinetic study in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Hayes, KC, et al., &amp; Cohen, R (2004). Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. <i>Archives of physical medicine and rehabilitation</i> 85(1) 29–34. DOI:<a href=\"https://doi.org/10.1016/s0003-9993(03)00651-8\">10.1016/s0003-9993(03)00651-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14970964/\">https://pubmed.ncbi.nlm.nih.gov/14970964</a></p></li><li><p>Blight, AR, &amp; Henney, HR (2009). Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. <i>Clinical therapeutics</i> 31(2) 328–335. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2009.02.004\">10.1016/j.clinthera.2009.02.004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19302905/\">https://pubmed.ncbi.nlm.nih.gov/19302905</a></p></li><li><p>Vollmer, T, et al., &amp; Henney, HR (2009). Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. <i>Clinical therapeutics</i> 31(10) 2215–2223. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2009.10.007\">10.1016/j.clinthera.2009.10.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19922892/\">https://pubmed.ncbi.nlm.nih.gov/19922892</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fampridine;
